Tech Mahindra, Nvidia To Advance Drug Safety With Agentic AI-Powered Pharmacovigilance
The solution will help streamline case intake, data transformation, quality control, and compliance management.
(Source: Freepik)
Tech Mahindra has announced a pharmacovigilance autonomous solution built with Nvidia AI software to advance drug safety management. The solution leverages agentic AI and automation to enhance the accuracy, speed, and efficiency of pharmacovigilance processes, addressing critical industry challenges such as manual delays and data overload.
The solution is powered by Tech Mahindra's TENO framework, which is built on Nvidia’s AI technology, and integrates the Nvidia AI Enterprise software platform, including NeMo, NIM microservices, and AI Blueprints. The solution will help streamline case intake, data transformation, quality control, and compliance management, thereby enabling an intelligent pharmacovigilance workflow.
Additionally, the large language model-powered AI agents within the solution autonomously handle case classification, prioritisation, and verification of pharmacovigilance emails to reduce the risk of human error.
Nikhil Malhotra, Chief Innovation Officer and Global Head of AI and emerging technologies, Tech Mahindra, said, “As the pharmaceutical industry navigates volumes of data during trials and post-launch, our collaboration with Nvidia leverages generative AI and multi-agent systems to streamline pharmacovigilance process.”
Tech Mahindra and Nvidia work together to provide better patient outcomes by bringing agentic AI-driven intelligence to pharmacovigilance. The pharmacovigilance industry manages over 1,000 daily cases of adverse drug reaction for major drugs. For instance, in the case of an email reporting adverse drug reaction, the AI-driven pharmacovigilance solution instantly flags, prioritises, and processes the request by eliminating human intervention that could potentially lead to delays and errors.
According to Tech Mahindra, the solution reduces turnaround times by up to 40%, enhances data accuracy by 30%, and cuts operational costs by 25%. This ensures timely case processing, regulatory adherence, and risk mitigation.
John Fanelli, Vice President, Enterprise Software, Nvidia, said, “AI is ideal for monitoring medicines throughout their lifecycle to support safety. Integrating AI into the Tech Mahindra TENO framework with Nvidia AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to help identify potential safety issues more effectively.”
Tech Mahindra has also expanded its TENO framework to encompass Nvidia AI Enterprise, offering customised AI agents to address industry challenges. The framework integrates Nvidia NeMo to accelerate generative AI pipeline for data collection and curation, coupled with Tech Mahindra’s VerifAI solution for data validation and governance.
